Lyra Therapeutics (NASDAQ:LYRA – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04), Zacks reports. Lyra Therapeutics had a negative return on equity of 125.07% and a negative net margin of 6,635.76%. The business had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.21 million. During the same quarter in the prior year, the company earned ($1.26) earnings per share.
Lyra Therapeutics Stock Performance
Shares of NASDAQ:LYRA opened at $0.17 on Friday. Lyra Therapeutics has a 52-week low of $0.16 and a 52-week high of $6.79. The company has a market capitalization of $11.26 million, a P/E ratio of -0.12 and a beta of -0.18. The company has a 50-day simple moving average of $0.19 and a 200 day simple moving average of $0.22.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a “neutral” rating and set a $2.00 price objective on shares of Lyra Therapeutics in a research note on Friday. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $4.50.
Lyra Therapeutics Company Profile
Lyra Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.
Featured Stories
- Five stocks we like better than Lyra Therapeutics
- Using the MarketBeat Dividend Yield Calculator
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Compound Interest and Why It Matters When Investing
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
- Profitably Trade Stocks at 52-Week Highs
- Why Costco Stock Is Poised to Hit $1,000 Again Soon
Receive News & Ratings for Lyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.